Abstract
Topical retinoids have been used in the treatment of pigmentary disorders such as melasma, actinic lentigines, and post-inflammatory hyperpigmentation. This article evaluates the clinical efficacy and tolerability of retinoid treatment for pigmentary disorders through an evidence-based approach.We searched the MEDLINE and The Cochrane Library databases using the keywords ‘retinoid’ combined with ‘melasma,’ ‘lentigines,’ or ‘postinflammatory hyperpigmentation.’ For each study, the methodology and outcomes were assessed according to specific criteria. There is fair evidence to support the use of topical tretinoin as a monotherapy in the treatment of melasma as well as in the treatment of lentigines (grade B). Adverse effects of topical retinoids are quite frequent, and include local skin irritation, erythema, and peeling, and their severity is mild to moderate. There is evidence to support the use of topical tretinoin in a fixed, triplecombination therapy (hydroquinone 4%/tretinoin 0.05%/fluocinolone acetonide 0.01%) for the treatment of melasma (grade B). There is poor evidence (grade C) to support the use of combination formulations for the treatment of lentigines, and large, randomized, double-blind, controlled trials are needed to further evaluate their use for this indication.
In conclusion, there is evidence to support the use of topical retinoids as monotherapy or in combination with other topical agents in the treatment of pigmentary disorders.
Similar content being viewed by others
References
Elias PM. Epidermal effects of retinoids: supramolecular observations and clinical implications. J Am Acad Dermatol 1986 Oct; 15 (4 Pt 2): 797–809
Yoshimura K, Tsukamoto K, Okazaki M, et al. Effects of all-trans retinoic acid on melanogenesis in pigmented skin equivalents and monolayer culture of melanocytes. J Dermatol Sci 2001 Aug; 27 Suppl. 1: S68–75
Romero C, Aberdam E, Larnier C, et al. Retinoic acid as modulator of UVB induced melanocyte differentiation: involvement of the melanogenic enzymes expression. J Cell Sci 1994 Apr; 107 (Pt 4): 1095–103
Watabe H, Soma Y, Ito M, et al. All-trans retinoic acid induces differentiation and apoptosis of murine melanocyte precursors with induction of the microphthalmia-associated transcription factor. J Invest Dermatol 2002 Jan; 118 (1): 35–42
Sackett D, Strauss S, Richardson W, et al. Evidence-based medicine: how to practice and teach EBM. London: Churchill Livingstone, 2001: 169–82
Griffiths CE, Finkel LJ, Ditre CM, et al. Topical tretinoin (retinoic acid) improves melasma: a vehicle-controlled, clinical trial. Br J Dermatol 1993 Oct; 129 (4): 415–21
Kimbrough-Green CK, Griffiths CE, Finkel LJ, et al. Topical retinoic acid (tretinoin) for melasma in black patients: a vehicle-controlled clinical trial. Arch Dermatol 1994 Jun; 130 (6): 727–33
Leenutaphong V, Nettakul A, Rattanasuwon P. Topical isotretinoin for melasma in Thai patients: a vehicle-controlled clinical trial. J Med Assoc Thai 1999 Sep; 82 (9): 868–75
Dogra S, Kanwar AJ, Parsad D. Adapalene in the treatment of melasma: a preliminary report. J Dermatol 2002 Aug; 29 (8): 539–40
Taylor SC, Torok H, Jones T, et al. Efficacy and safety of a new triplecombination agent for the treatment of facial melasma. Cutis 2003 Jul; 72 (1): 67–72
Chan R, Park KC, Lee MH, et al. A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma. Br J Dermatol 2008 Sep; 159 (3): 697–703
Grimes P, Kelly AP, Torok H, et al. Community-based trial of a triplecombination agent for the treatment of facial melasma. Cutis 2006 Mar; 77 (3): 177–84
Torok HM, Jones T, Rich P, et al. Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma. Cutis 2005 Jan; 75 (1): 57–62
Kang WH, Chun SC, Lee S. Intermittent therapy for melasma inAsian patients with combined topical agents (retinoic acid, hydroquinone and hydrocortisone): clinical and histological studies. J Dermatol 1998 Sep; 25 (9): 587–96
Kauh YC, Zachian TF. Melasma. Adv Exp Med Biol 1999; 455: 491–9
Grimes PE. Amicrosponge formulation of hydroquinone 4% and retinol 0.15% in the treatment of melasma and postinflammatory hyperpigmentation. Cutis 2004 Dec; 74 (6): 362–8
Grimes PE. An efficacy study of 3 commercially available hydroquinone 4% treatments for melasma. Cutis 2007 Dec; 80 (6): 497–502
Keeling J, Cardona L, Benitez A, et al. Mequinol 2%/tretinoin 0.01% topical solution for the treatment of melasma in men: a case series and review of the literature. Cutis 2008 Feb; 81 (2): 179–83
Rafal ES, Griffiths CE, Ditre CM, et al. Topical tretinoin (retinoic acid) treatment for liver spots associated with photodamage. N Engl J Med 1992 Feb 6; 326 (6): 368–74
Kang S, Goldfarb MT, Weiss JS, et al. Assessment of adapalene gel for the treatment of actinic keratoses and lentigines: a randomized trial. J Am Acad Dermatol 2003 Jul; 49 (1): 83–90
Ellis CN, Weiss JS, Hamilton TA, et al. Sustained improvement with prolonged topical tretinoin (retinoic acid) for photoaged skin. J Am Acad Dermatol 1990 Oct; 23 (4 Pt 1): 629–37
Kang S, Bergfeld W, Gottlieb AB, et al. Long-term efficacy and safety of tretinoin emollient cream 0.05% in the treatment of photodamaged facial skin: a two-year, randomized, placebo-controlled trial. Am J Clin Dermatol 2005; 6 (4): 245–53
Weiss JS, Shavin JS, Nighland M, et al. Tretinoin microsphere gel 0.1% for photodamaged facial skin: a placebo-controlled trial. Cutis 2006 Dec; 78 (6): 426–32
Weinstein GD, Nigra TP, Pochi PE, et al. Topical tretinoin for treatment of photodamaged skin: a multicenter study. Arch Dermatol 1991 May; 127 (5): 659–65
Phillips TJ, Gottlieb AB, Leyden JJ, et al. Efficacy of 0.1% tazarotene cream for the treatment of photodamage: a 12-month multicenter, randomized trial: Tazarotene Cream Photodamage Clinical Study Group. Arch Dermatol 2002 Nov; 138 (11): 1486–93
Lowe N, Gifford M, Tanghetti E, et al. Tazarotene 0.1% cream versus tretinoin 0.05% emollient cream in the treatment of photodamaged facial skin: a multicenter, double-blind, randomized, parallel-group study. J Cosmet Laser Ther 2004 Jun; 6 (2): 79–85
Fleischer Jr AB, Schwartzel EH, Colby SI, et al. The combination of 2% 4-hydroxyanisole (mequinol) and 0.01% tretinoin is effective in improving the appearance of solar lentigines and related hyperpigmented lesions in two double-blind multicenter clinical studies. J Am Acad Dermatol 2000 Mar; 42 (3): 459–67
Jarratt M. Mequinol 2%/tretinoin 0.01% solution: an effective and safe alternative to hydroquinone 3% in the treatment of solar lentigines. Cutis 2004 Nov; 74 (5): 319–22
Ortonne JP, Camacho F, Wainwright N, et al. Safety and efficacy of combined use of 4-hydroxyanisole (mequinol) 2%/tretinoin 0.01% solution and sunscreen in solar lentigines. Cutis 2004 Oct; 74 (4): 261–4
Draelos ZD. The combination of 2% 4-hydroxyanisole (mequinol) and 0.01% tretinoin effectively improves the appearance of solar lentigines in ethnic groups. J Cosmet Dermatol 2006 Sep; 5 (3): 239–44
Yoshimura K, Harii K, Aoyama T, et al. Experience with a strong bleaching treatment for skin hyperpigmentation in Orientals. Plast Reconstr Surg 2000 Mar; 105 (3): 1097–108
Bulengo-Ransby SM, Griffiths C, Kimbrough-Green CK, et al. Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in black patients. N Engl J Med 1993 May; 328: 1438–43
Grimes PE, Callender V. Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin; a double-blind, randomized, vehicle-controlled study. Cutis 2006 Jan; 77: 45–50
Jacyk WK. Adapalene in the treatment of African patients. J Eur Acad Dermatol Venereol 2001; 15 Suppl. 3: 37–42
Kligman AM, Willis I. A new formula for depigmenting human skin. Arch Dermatol 1975 Jan; 111 (1): 40–8
Palumbo A, D’Ischia M, Misuraca G, et al. Mechanism of inhibition of melanogenesis by hydroquinone. Biochem Biophys Acta 1991 Jan; 1073 (1): 85–90
Yoshimura K, Momosawa A, Aiba E et al. Clinical trial of bleaching treatment with 10% all-trans retinol gel. Dermatol Surg 2003 Feb; 29 (2): 155–60
Nair X, Parab P, Suhr L, et al. Combination of 4-hydroyanisole and all-trans retinoic acid produces synergistic skin depigmentation in swine. J Invest Dermatol 1993 Aug; 101 (2): 145–9
Acknowledgments
No sources of funding were used to assist in the preparation of this review. Prof. Ortonne has received grants from Schering-Plough, Abbott, Merk-Serono, Centocor, Wyeth, Janssen-Cilag, Meda Pharma, Pierre Fabre, Galderma, and Leo Pharma. Dr Kang has received a grant from Galderma. Drs Valerio and Bahadoran have no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kang, H.Y., Valerio, L., Bahadoran, P. et al. The Role of Topical Retinoids in the Treatment of Pigmentary Disorders. AM J Clin Dermatol 10, 251–260 (2009). https://doi.org/10.2165/00128071-200910040-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128071-200910040-00005